ferroin has been researched along with Multiple Myeloma in 1 studies
*Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Carrasco, RD; Chauhan, D; Das, DS; Li, S; Munshi, N; Qi, J; Ray, A; Samur, MK; Song, Y; Tai, YT | 1 |
1 other study(ies) available for ferroin and Multiple Myeloma
| Article | Year |
|---|---|
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mice; Multiple Myeloma; Phenanthrolines; Prognosis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Trans-Activators; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |